ClexBio is an Oslo‑based startup developing bioengineered human blood vessels for transplant by manipulating living cells at the microscale using its proprietary CLEX technology. The company is led by Co‑Founder and CEO Dr. Armend G. Håti and Co‑Founder and CSO Dr. Manuel Schweikle. ClexBio is already commercializing early R&D applications in partnership with Cambridge‑based Sphere Fluidics. It raised US$2.2M in seed financing to expand operations and continue development efforts. The financing consisted of US$1.2M from angel investors across Europe and Asia and US$1M in non‑dilutive grants. The company intends to use the funds to continue to expand operations and development efforts.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2021